Standard BioTools Statistics
Total Valuation
LAB has a market cap or net worth of $783.14 million. The enterprise value is $478.97 million.
Important Dates
The next estimated earnings date is Tuesday, November 5, 2024, after market close.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LAB has 371.15 million shares outstanding. The number of shares has increased by 161.10% in one year.
| Shares Outstanding | 371.15M |
| Shares Change (YoY) | +161.10% |
| Shares Change (QoQ) | +26.59% |
| Owned by Insiders (%) | 1.67% |
| Owned by Institutions (%) | 48.34% |
| Float | 235.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.19 |
| Forward PS | 3.76 |
| PB Ratio | 1.53 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.88, with a Debt / Equity ratio of 0.18.
| Current Ratio | 3.88 |
| Quick Ratio | 3.45 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.77 |
Financial Efficiency
Return on equity (ROE) is -33.51% and return on invested capital (ROIC) is -15.71%.
| Return on Equity (ROE) | -33.51% |
| Return on Assets (ROA) | -13.28% |
| Return on Capital (ROIC) | -15.71% |
| Revenue Per Employee | $252,876 |
| Profits Per Employee | -$305,495 |
| Employee Count | 539 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 2.94 |
Taxes
In the past 12 months, LAB has paid $71,000 in taxes.
| Income Tax | 71,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.74% in the last 52 weeks. The beta is 1.58, so LAB's price volatility has been higher than the market average.
| Beta (5Y) | 1.58 |
| 52-Week Price Change | -26.74% |
| 50-Day Moving Average | 1.99 |
| 200-Day Moving Average | 2.27 |
| Relative Strength Index (RSI) | 57.10 |
| Average Volume (20 Days) | 1,685,628 |
Short Selling Information
The latest short interest is 22.23 million, so 5.99% of the outstanding shares have been sold short.
| Short Interest | 22.23M |
| Short Previous Month | 21.80M |
| Short % of Shares Out | 5.99% |
| Short % of Float | 9.46% |
| Short Ratio (days to cover) | 7.01 |
Income Statement
In the last 12 months, LAB had revenue of $136.30 million and -$164.66 million in losses. Loss per share was -$0.80.
| Revenue | 136.30M |
| Gross Profit | 41.07M |
| Operating Income | -113.14M |
| Pretax Income | -118.58M |
| Net Income | -164.66M |
| EBITDA | -104.31M |
| EBIT | -113.14M |
| Loss Per Share | -$0.80 |
Full Income StatementBalance Sheet
The company has $394.71 million in cash and $90.55 million in debt, giving a net cash position of $304.16 million or $0.82 per share.
| Cash & Cash Equivalents | 394.71M |
| Total Debt | 90.55M |
| Net Cash | 304.16M |
| Net Cash Per Share | $0.82 |
| Equity (Book Value) | 510.26M |
| Book Value Per Share | 1.37 |
| Working Capital | 356.22M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$127.00 million and capital expenditures -$3.70 million, giving a free cash flow of -$130.70 million.
| Operating Cash Flow | -127.00M |
| Capital Expenditures | -3.70M |
| Free Cash Flow | -130.70M |
| FCF Per Share | -$0.35 |
Full Cash Flow StatementMargins
Gross margin is 30.13%, with operating and profit margins of -83.01% and -87.05%.
| Gross Margin | 30.13% |
| Operating Margin | -83.01% |
| Pretax Margin | -87.00% |
| Profit Margin | -87.05% |
| EBITDA Margin | -76.53% |
| EBIT Margin | -83.01% |
| FCF Margin | -95.89% |
Dividends & Yields
LAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -161.10% |
| Shareholder Yield | -161.10% |
| Earnings Yield | -21.03% |
| FCF Yield | -16.69% |
Analyst Forecast
The average price target for LAB is $3.00, which is 42.18% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 42.18% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 31.13% |
| EPS Growth Forecast (5Y) | -61.74% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LAB has an Altman Z-Score of -0.49 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.49 |
| Piotroski F-Score | 2 |